Literature DB >> 26066372

Effect of fasting on the size of lymphangioleiomyomas in patients with lymphangioleiomyomatosis.

Angelo M Taveira-DaSilva1, Amanda M Jones2, Patricia Julien-Williams2, Thomas Shawker3, Connie G Glasgow2, Mario Stylianou4, Joel Moss2.   

Abstract

BACKGROUND: Lymphangioleiomyomas occur in 38% of patients with sporadic lymphangioleiomyomatosis (LAM) and may cause pain and increased abdominal girth, mimicking the presence of a malignancy. Lymphatic involvement in LAM is closely associated with elevated serum levels of vascular endothelium growth factor-D (VEGF-D). Because lymphangioleiomyomas undergo diurnal variation in volume, we hypothesized that daytime ingestion of food, by increasing chyle formation and lymphatic flow, is the cause of an increase in lymphangioleiomyoma volume.
METHODS: Subjects had abdominopelvic sonograms and blood drawn for measurement of serum VEGF-D levels under nonfasting (day 1) and fasting (day 2) conditions. The size of the lymphangioleiomyomas was determined by a radiologist who was blinded to the subjects' status. The Wilcoxon signed rank test was used to determine whether the nonfasting tumor size was different from the fasting tumor size.
RESULTS: Thirty-five women were studied (aged 45.2 ± 8.5 years; FEV1, 82% ± 25%; diffusing capacity of the lung for carbon monoxide, 64% ± 25% predicted). Images suitable for volume measurements were obtained in 30 subjects. Fasting decreased the tumor size by 20.7 ± 39.3 cm3 (24% ± 40%, P < .001). Fasting VEGF-D levels (10,650 ± 900 pg/mL) were not significantly different from nonfasting values (12,100 ± 800 pg/mL, P = .56).
CONCLUSIONS: Lymphangioleiomyoma volume decreased during the fasting state. Conversely, a combination of food intake and decreased chyle flow through lymphatics partially obstructed by LAM cells may account for increases in lymphangioleiomyoma size. Imaging studies performed under fasting conditions may help in determining whether an abdominal tumor is a result of LAM or malignancy.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26066372      PMCID: PMC4594622          DOI: 10.1378/chest.15-0456

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  37 in total

1.  Cytologic, immunocytochemical and ultrastructural characterization of lymphangioleiomyomatosis cell clusters in chylous effusions of patients with lymphangioleiomyomatosis.

Authors:  Keiko Mitani; Toshio Kumasaka; Hiroyuki Takemura; Takuo Hayashi; Yoko Gunji; Makiko Kunogi; Taeko Akiyoshi; Kazuhisa Takahashi; Koichi Suda; Kuniaki Seyama
Journal:  Acta Cytol       Date:  2009 Jul-Aug       Impact factor: 2.319

2.  Nutritional management in chyle leaks and chylous effusions.

Authors:  Anna C Bibby; Nick A Maskell
Journal:  Br J Community Nurs       Date:  2014-10

3.  Severity and outcome of cystic lung disease in women with tuberous sclerosis complex.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Jianhua Yao; Mario Stylianou; Joel Moss
Journal:  Eur Respir J       Date:  2014-12-23       Impact factor: 16.671

Review 4.  Lymphatic manifestations of lymphangioleiomyomatosis.

Authors:  R Gupta; M Kitaichi; Y Inoue; R Kotloff; F X McCormack
Journal:  Lymphology       Date:  2014-09       Impact factor: 1.286

5.  Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.

Authors:  Angelo M Taveira-DaSilva; Olanda Hathaway; Mario Stylianou; Joel Moss
Journal:  Ann Intern Med       Date:  2011-06-21       Impact factor: 25.391

6.  Computed tomographic features of lymphangioleiomyomatosis: evaluation in 138 patients.

Authors:  Kazunori Tobino; Takeshi Johkoh; Kiminori Fujimoto; Fumikazu Sakai; Hiroaki Arakawa; Masatoshi Kurihara; Toshio Kumasaka; Kengo Koike; Kazuhisa Takahashi; Kuniaki Seyama
Journal:  Eur J Radiol       Date:  2014-12-19       Impact factor: 3.528

7.  Therapeutic strategies for idiopathic chylothorax.

Authors:  Ralph Epaud; Beatrice Dubern; Michele Larroquet; Aline Tamalet; Nathalie Guillemot; Chantal Maurage; Annick Clement; Brigitte Fauroux
Journal:  J Pediatr Surg       Date:  2008-03       Impact factor: 2.545

8.  Serum vascular endothelial growth factor-D levels in patients with lymphangioleiomyomatosis reflect lymphatic involvement.

Authors:  Connie G Glasgow; Nilo A Avila; Jing-Ping Lin; Mario P Stylianou; Joel Moss
Journal:  Chest       Date:  2009-05       Impact factor: 9.410

9.  The use of fat-free human milk in infants with chylous pleural effusion.

Authors:  G M Chan; E Lechtenberg
Journal:  J Perinatol       Date:  2007-06-07       Impact factor: 2.521

10.  Conservative versus surgical management of chylothorax.

Authors:  B C Marts; K S Naunheim; A C Fiore; D G Pennington
Journal:  Am J Surg       Date:  1992-11       Impact factor: 2.565

View more
  3 in total

1.  Sirolimus and Autophagy Inhibition in Lymphangioleiomyomatosis: Results of a Phase I Clinical Trial.

Authors:  Souheil El-Chemaly; Angelo Taveira-Dasilva; Hilary J Goldberg; Elizabeth Peters; Mary Haughey; Don Bienfang; Amanda M Jones; Patricia Julien-Williams; Ye Cui; Julian A Villalba; Shefali Bagwe; Rie Maurer; Ivan O Rosas; Joel Moss; Elizabeth P Henske
Journal:  Chest       Date:  2017-02-10       Impact factor: 9.410

2.  Long-Term Effect of Sirolimus on Serum Vascular Endothelial Growth Factor D Levels in Patients With Lymphangioleiomyomatosis.

Authors:  Angelo M Taveira-DaSilva; Amanda M Jones; Patricia Julien-Williams; Mario Stylianou; Joel Moss
Journal:  Chest       Date:  2017-05-19       Impact factor: 9.410

3.  EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.

Authors:  Angelo M Taveira-DaSilva; Joel Moss
Journal:  Expert Opin Orphan Drugs       Date:  2016-03-07       Impact factor: 0.694

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.